Phase IB trial of ACY-1215 (Ricolinostat) combined with nab-paclitaxel in metastatic breast cancer.

被引：0
|
作者：
Kalinsky, Kevin
Onishi, Maika
Yu, JiYang
Trivedi, Meghna S.
Accordino, Melissa Kate
Crew, Katherine D.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.1058
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1058
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase IB trial of ACY-1215 (ricolinostat) combined with nab-paclitaxel in metastatic breast cancer (MBC)
    Kalinsky, Kevin
    Chiuzan, Cody
    Onishi, Maika
    Trivedi, Meghna S.
    Accordino, Melissa
    Zeleke, Tizita
    Pan, Qingfei
    Kelly, Sean
    Honan, Erin
    Wu, Ruby
    Fenn, Kathleen
    Crew, Katherin D.
    Hershman, Dawn L.
    Maurer, Matthew
    Yu, Jiyang
    Silva, Jose
    CANCER RESEARCH, 2020, 80 (04)
  • [2] Multi-center phase IB trial of ACY-1215 (Ricolinostat) combined with nab-paclitaxel in unresectable or metastatic breast cancer
    Onishi, M.
    Chiuzan, C.
    Fasano, J.
    Crew, K.
    Accordino, M.
    Tiersten, A.
    Shapiro, C.
    Jarpe, M.
    Qualye, S.
    Trede, N.
    Wheeler, C.
    Hershman, D.
    Silva, J.
    Maurer, M.
    Kalinksy, K.
    CANCER RESEARCH, 2017, 77
  • [3] Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple negative breast cancer (mTNBC).
    Adams, Sylvia
    Diamond, Jennifer Robinson
    Hamilton, Erika Paige
    Pohlmann, Paula Raffin
    Tolaney, Sara M.
    Molinero, Luciana
    He, Xian
    Waterkamp, Daniel
    Funke, Roel Peter
    Powderly, John D.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [4] Phase II trial of nab-paclitaxel in metastatic breast cancer patients with visceral metastases
    Yizhao Xie
    Chengcheng Gong
    Jian Zhang
    Leiping Wang
    Jun Cao
    Zhonghua Tao
    Ting Li
    Yannan Zhao
    Yi Li
    Shihui Hu
    Biyun Wang
    Xichun Hu
    BMC Cancer, 21
  • [5] A Phase II study of weekly nab-paclitaxel in combination with gemcitabine in patients with metastatic breast cancer.
    Zhao, Yannan
    Lv, Fangfang
    Chen, Shen
    Lu, Yunhua
    Cao, Enying
    Wang, Zhonghua
    Zhang, Jian
    Zhang, Sheng
    Cao, Jun
    Zheng, Chunlei
    Wang, Leiping
    Wang, Biyun
    Hu, Xichun
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [6] nab-Paclitaxel for the Treatment of Aggressive Metastatic Breast Cancer
    Glueck, Stefan
    CLINICAL BREAST CANCER, 2014, 14 (04) : 221 - 227
  • [7] A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer
    Andrew H. Ko
    Thach-Giao Truong
    Emily Kantoff
    Kimberly A. Jones
    Elizabeth Dito
    Anna Ong
    Margaret A. Tempero
    Cancer Chemotherapy and Pharmacology, 2012, 70 : 875 - 881
  • [8] A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer
    Ko, Andrew H.
    Truong, Thach-Giao
    Kantoff, Emily
    Jones, Kimberly A.
    Dito, Elizabeth
    Ong, Anna
    Tempero, Margaret A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (06) : 875 - 881
  • [9] Carboplatin, nab-paclitaxel and bevacizumab as first-line treatment for metastatic breast cancer.
    Lo, S. S.
    Guo, R.
    Czaplicki, K. L.
    Robinson, P. A.
    Gaynor, E.
    Barhamand, F. B.
    Schulz, W. C.
    Kash, J. J.
    Horvath, L. E.
    Bayer, R. A.
    Petrowsky, C.
    De la Torre, R.
    Park, J. H.
    Albain, K. S.
    CANCER RESEARCH, 2012, 72
  • [10] Phase Ib and Expansion Study of Gemcitabine, Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer
    Perez, Kimberly
    Chiarella, Anna M.
    Cleary, James M.
    Horick, Nora
    Weekes, Colin
    Abrams, Thomas
    Blaszkowsky, Lawrence
    Enzinger, Peter
    Giannakis, Marios
    Goyal, Lipika
    Meyerhardt, Jeffrey A.
    Rubinson, Douglas
    Yurgelun, Matthew B.
    Goessling, Wolfram
    Giantonio, Bruce J.
    Brais, Lauren
    Germon, Victoria
    Stonely, Danielle
    Raghavan, Srivatsan
    Bakir, Basil
    Das, Koushik
    Pitarresi, Jason R.
    Aguirre, Andrew J.
    Needle, Michael
    Rustgi, Anil K.
    Wolpin, Brian M.
    ONCOLOGIST, 2023, 28 (05): : 425 - 432
12345